Replies to post #386315 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Would add 2 things about NWBO's therapy:

1) It is not very scalable: it is personalized and parenteral.

2) It barely moves the needle.

Am not a NWBO hater but it is, like many oncology plays (not all), not effective enough for enough people for long enough to be worth much.

OTOH, working for 70% of AD patients in a clinically meaningful way with an oral medication would be huge. It is scalable and definitely moves the needle. In addition, 30% of AD patients are misdiagnosed so...70% is about as good as you can get (right now.)

[dennisdave]

How much cash do they have on hand with relation to their burn rate?

You are absolutely right, NWBOs cash position is of much greater concern than Anavex's cash position is, and has been for years now. However, the dilution of present shareholders to bring in cash converting to cash from other sources such as revenue, big pharma license/investments etc, and thus the halting of dilution of retail shareholders is a pivoting point for every nonrevenue biotech including Anavex.